Invitae
African American Prostate Cancer Patients Get More VUS, Fewer Actionable Results, Studies Show
Research presented at ASCO's annual meeting underscores the need for more cancer susceptibility studies in diverse populations, experts say.
Allelica, Invitae Partner to Build Ancestry-Informed Polygenic Risk Score for Breast Cancer
The companies plan to jointly develop and validate a PRS that can be clinically implemented across diverse genetic ancestries. Â
Invitae Launches Study to Generate Real-World Data on Personalized MRD Test Across Tumor Types
Premium
The 1,000-patient MARIA trial may provide insights into the types of cases for which oncologists are willing to use Invitae's test to track recurrence and guide treatment.
Invitae Garners CE-IVD Mark for Two Comprehensive Genomic Profiling Tests
FusionPlex Dx and LiquidPlex Dx identify targeted treatment opportunities for cancer patients and can now be adopted by facilities in Europe with sequencing capabilities.
Invitae Launches Ciitizen Genome Information Management Platform at JPM
The company believes the platform will expedite its longstanding goal of amassing genomic and other information from patients through their lifespan to fuel discoveries and improve care.